Indications and uses
■ Temporarily relieves symptoms associated with motion sickness, including: ■ nausea ■ headache with nausea ■ vomiting ■ dizziness ■ sour stomach
■ Temporarily relieves symptoms associated with motion sickness, including: ■ nausea ■ headache with nausea ■ vomiting ■ dizziness ■ sour stomach
■ Use as directed. Adults and children 12 years and over At onset of symptoms, dissolve 2 tablets under tongue every 4 hours until relieved, up to 6 times per day. Children 6 years to under 12 years At onset of symptoms, dissolve 1 tablet under tongue every 4 hours until relieved, up to 6 times per day.
Temporarily relieves symptoms associated with motion sickness, including nausea, headache with nausea, vomiting, dizziness, sour stomach
| Active Ingredients | Purpose |
| Cocculus Indicus 30X HPUS | nausea, dizziness, vomiting |
Nux Vomica 6X HPUS (0.0000016% Alkaloids, calculated) | sour stomach, nausea |
| Petroleum 12X HPUS | nausea, dizziness |
| Tabacum 6X HPUS | headache with nausea, vomiting |
"HPUS" is the Homeopathic Pharmacopoeia of the United States.
■ Temporarily relieves symptoms associated with motion sickness, including: ■ nausea ■ headache with nausea ■ vomiting ■ dizziness ■ sour stomach
symptoms persist more than 72 hours or worsen.
Ask a health professional before use.
■ Use as directed.
| Adults and children
12 years and over | At onset of symptoms, dissolve 2 tablets under tongue
every 4 hours until relieved, up to 6 times per day. |
| Children 6 years
to under 12 years | At onset of symptoms, dissolve 1 tablet under tongue
every 4 hours until relieved, up to 6 times per day. |
Acacia Gum, Lactose.
www.hylands.com or care@hylands.com
Temporarily relieves symptoms associated with motion sickness, including:
nausea headache with nausea vomiting dizziness sour stomach
Directions ■ Use as directed.
| Adults and children
12 years and over | At onset of symptoms, dissolve 2 tablets under tongue
every 4 hours until relieved, up to 6 times per day. |
| Children 6 years
to under 12 years | At onset of symptoms, dissolve 1 tablet under tongue
every 4 hours until relieved, up to 6 times per day. |
Hyland's
NATURALS™
MOTION
SICKNESS*
NON-DROWSY
• NAUSEA
• VOMITING
• DIZZINESS
50
QUICK-DISSOLVING TABLETS
HOMEOPATHIC
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 54973-9147-1 | Motion Sickness | 50 in 1 BOTTLE, PLASTIC | TABLET, SOLUBLE | 50 | 4 | |
| 54973-9147-2 | Motion Sickness | 16 in 1 BOTTLE, PLASTIC | TABLET, SOLUBLE | 16 | 4 | |
| 54973-9147-2 | Motion Sickness | 1 in 1 CARTON | TABLET, SOLUBLE | 1 | 4 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 54973-9147 | MOTION SICKNESS (STRYCHNOS NUX-VOMICA SEED, TOBACCO LEAF, KEROSENE, AND ANAMIRTA COCCULUS SEED) TABLET, SOLUBLE [HYLAND'S CONSUMER HEALTH INC.] | 4 | Current NDC, Legacy NDC, 3 package rows | 20220911_13ba963e-94cb-495b-bd1c-8acf214b6f6e.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ANAMIRTA COCCULUS SEED | ACTIVE INGREDIENT | 810258W28U | 1 | |
| KEROSENE | ACTIVE INGREDIENT | 1C89KKC04E | 1 | |
| STRYCHNOS NUX-VOMICA SEED | ACTIVE INGREDIENT | 269XH13919 | 1 | |
| TOBACCO LEAF | ACTIVE INGREDIENT | 6YR2608RSU | 1 | |
| ANAMIRTA COCCULUS SEED | ACTIVE MOIETY | 810258W28U | 1 | |
| KEROSENE | ACTIVE MOIETY | 1C89KKC04E | 1 | |
| STRYCHNOS NUX-VOMICA SEED | ACTIVE MOIETY | 269XH13919 | 1 | |
| TOBACCO LEAF | ACTIVE MOIETY | 6YR2608RSU | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 54973-9147 | 54973-9147-1, 54973-9147-2 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LACTOSE | J2B2A4N98G | IACT |
| STRYCHNOS NUX-VOMICA SEED | 269XH13919 | ACTIB |
| TOBACCO LEAF | 6YR2608RSU | ACTIB |
| KEROSENE | 1C89KKC04E | ACTIB |
| ANAMIRTA COCCULUS SEED | 810258W28U | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Motion Sickness | STRYCHNOS NUX-VOMICA SEED, TOBACCO LEAF, KEROSENE, AND ANAMIRTA COCCULUS SEED | Hyland's Consumer Health Inc. | 13ba963e-94cb-495b-bd1c-8acf214b6f6e | 2022-09-08 | Warnings | 54973-9147-1 54973-9147-2 54973-9147 54973914701 54973914702 e831b8e5-6f76-bb61-e053-2a95a90a4cc6 13ba963e-94cb-495b-bd1c-8acf214b6f6e |
Adverse event summaries are temporarily unavailable. Other product information remains available.